CDC's Advisory Committee on Immunization Practices (ACIP) met June 26 – 28 to discuss data on multiple vaccines. The agenda and presentations are online. Below is a readout of the votes made during the meeting.
Recommendations made by the ACIP are reviewed by the CDC Director and, if adopted, become the official CDC public health guidance for safe use of the vaccine in the U.S. and are published as official recommendations in the Morbidity and Mortality Weekly Report (MMWR).
Wednesday, June 26, 2024
Respiratory Syncytial Virus Vaccines – Adults
ACIP met to review data on 3 RSV vaccines (from GSK, Moderna and Pfizer) for adults.
Background
- According to estimates prior to the COVID-19 pandemic, RSV caused approximately 60,000–160,000 hospitalizations and 6,000–10,000 deaths per year among adults ages 65 years and older in the U.S.
Vote
- ACIP passed a unanimous motion (11-0) recommending adults ages 75 and older receive a single dose of RSV vaccine.
- ACIP passed a unanimous motion (11-0) recommending adults ages 60 to 74 who are at increased risk of severe RSV disease receive a single dose of RSV vaccine.
- These are people who have certain chronic medical conditions, such as lung or heart disease, or they live in nursing homes.
Result
- CDC updated it's RSV vaccination recommendation for adults: CDC Updates RSV Vaccination Recommendation for Adults | CDC Online Newsroom | CDC
Vaxelis
ACIP met to discuss whether DTaP-IPV-Hib-HepB (Vaxelis) should be included with PRP-OMP (PedvaxHIB) in the preferential recommendation for American Indian and Alaska Native (AI/AN) infants based on the Haemophilus influenzae type b (Hib) component.
Vote
- ACIP passed a unanimous motion (11-0) recommending that Vaxelis be included with PRP-OMP (PedvaxHIB) in the preferential recommendation for AI/AN infants based on Hib component.
- The Vaccines for Children (VFC) resolution for Vaxelis was also approved.
Other topics discussed
- Dengue Vaccine
- ACIP met to discuss the discontinuation of Dengue Tetravalent Vaccine (Live, Attenuated) [Dengvaxia®] in the U.S.
- Chikungunya Vaccine
Thursday, June 27, 2024
COVID-19 Vaccine
ACIP met to review a universal recommendation for everyone ages 6 months and older to receive the updated 2024 – 2025 COVID-19 vaccine.
Background
- Data continue to show the importance of vaccination to protect against COVID-19.
- The updated 2024–2025 COVID-19 vaccine is expected to be available in fall 2024 with the goal of providing the best protection against currently circulating strains.
Vote
- ACIP passed a unanimous motion (11-0) recommending the updated 2024-2025 COVID-19 vaccine as authorized or approved by FDA in persons ages 6 months and older.
Result
- CDC recommended the updated 2024-2025 COVID-19 vaccines: CDC Recommends Updated 2024-2025 COVID-19 and Flu Vaccines for Fall/Winter Virus Season | CDC Online Newsroom | CDC
Influenza Vaccines
ACIP met to discuss recommendations for U.S. influenza vaccines for the 2024-2025 season and recommendations of vaccination for solid organ transplant recipients.
Background
- Updated 2024-2025 flu vaccines will all be trivalent and will protect against an H1N1, H3N1 and a B/Victoria lineage virus.
Vote
- ACIP passed a unanimous motion (11-0) recommending routine vaccination for everyone 6 months and older.
- ACIP passed a unanimous motion (11-0) recommending that high-dose (HD-IIV3) and adjuvanted (aIIV3) inactivated influenza vaccines are acceptable options for influenza vaccination of solid organ transplant recipients who are 18-64 years old and who are taking immunosuppressive medication regimens, without a preference over other age appropriate inactivated or recombinant influenza vaccines.
Result
- CDC recommended the updated 2024-2025 flu vaccines: CDC Recommends Updated 2024-2025 COVID-19 and Flu Vaccines for Fall/Winter Virus Season | CDC Online Newsroom | CDC
Pneumococcal Vaccines
ACIP met to discuss recommendations for PCV21 for adults in the United States aged 19 years and older who currently have a recommendation to receive a pneumococcal conjugate vaccine (PCV).
Background
- PCV21 covers 81% of the pneumococcal serotypes commonly found in adults and gives healthcare providers another option for protecting adult patients from pneumococcal infections.
Vote
- ACIP passed a unanimous motion (11-0) recommending PCV21 as an option for adults aged 19 years and older who currently have a recommendation to receive a dose of PCV.
Friday, June 28, 2024
Meningococcal Vaccines
ACIP is revisiting the adolescent meningococcal vaccine schedule to optimize protection for the higher-risk ages, considering the recent epidemiology, the duration of vaccine-induced protection, and the availability of GSK's new pentavalent (ABCWY) vaccine. This discussion will continue at the October 2024 ACIP meeting.
RSV Vaccines – Maternal/Pediatric
Real-world data on vaccine safety and effectiveness were discussed at ACIP for the first time after a maternal vaccine and a long-acting monoclonal antibody to protect infants from RSV were launched for the 2023-2024 season.
Summary
- CDC continues to recommend RSV immunizations to protect all babies from severe RSV.
- Nirsevimab, the monoclonal antibody for infants, was effective against RSV-associated emergency department visits and hospitalizations.
Human Papillomavirus Vaccines
ACIP discussed the launch of a new work group on HPV that will have its first meeting in July 2024. This workgroup will look at the number of doses currently recommended, the language around the age for routine vaccination, and sub-group guidance on shared clinical decision-making for 27-to 45-year-olds.
